Neurocrine Biosciences Inc. reports biopharmaceutical developments across neurological, psychiatric, endocrine and immunological disorders. Recurring updates include commercial and clinical information for INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease, CRENESSITY for classic congenital adrenal hyperplasia, and approved therapies for endometriosis and uterine fibroids.
Company news also covers CAHtalyst clinical data, peer-reviewed publications on glucocorticoid dosing and the Tardive Dyskinesia Impact Scale, pipeline programs such as NBIP-'2118, financial results, healthcare conference participation, and governance or capital-structure matters tied to Neurocrine's public-company reporting.
Neurocrine Biosciences (Nasdaq: NBIX) will present at the Goldman Sachs 42nd Annual Global Healthcare Conference on June 8, 2021, at 1:20 p.m. ET. CEO Kevin Gorman will lead the presentation. Attendees can access the live webcast on the company's website, with a replay available about an hour after the event, archived for one month. Neurocrine focuses on developing treatments for neurological and endocrine disorders, with a portfolio that includes FDA-approved therapies for tardive dyskinesia, Parkinson's disease, and more.
Neurocrine Biosciences (Nasdaq: NBIX) will present at the 2021 RBC Capital Markets Healthcare Conference on May 18, 2021 at 10:55 a.m. Eastern Time. The presentation will feature CFO Matt Abernethy and CMO Eiry Roberts. Interested parties can access the live webcast on the company's website, with a replay available afterward for one month. Neurocrine focuses on innovative treatments for neurological and psychiatric disorders, with a portfolio that includes FDA-approved therapies for tardive dyskinesia and Parkinson's disease.
Neurocrine Biosciences (NBIX) reported $236.6 million in total revenues for Q1 2021, slightly down from $237.1 million in Q1 2020. Product sales from INGREZZA were $231 million. GAAP net income decreased to $32.1 million, with diluted earnings per share at $0.33 compared to $0.39 in the previous year. The company revised its full-year expense guidance to $855-$905 million for GAAP R&D and SG&A. Despite lower refill rates attributed to seasonal payor dynamics and COVID disruptions, new patient starts for INGREZZA improved late in the quarter, signaling a potential recovery.
Neurocrine Biosciences (Nasdaq: NBIX) will present at the Bank of America 2021 Healthcare Conference on May 11, 2021, at 11:00 a.m. Eastern Time. CEO Kevin Gorman will lead the presentation, which will be webcast live on the company's website. A replay will be available shortly after the event and archived for a month. Neurocrine focuses on developing treatments for neurological, endocrine, and psychiatric disorders, offering FDA-approved therapies for conditions like tardive dyskinesia and Parkinson's disease.
Neurocrine Biosciences (Nasdaq: NBIX) announced the appointment of Johanna Mercier to its Board of Directors. Mercier, currently the Chief Commercial Officer at Gilead Sciences, brings extensive experience from her 25-year tenure at Bristol Myers Squibb, where she led successful commercial strategies, particularly in oncology. Her expertise is anticipated to enhance the company's direction in developing treatments for neurological and endocrine disorders. The announcement underscores the company's commitment to strengthening its leadership team.
Neurocrine Biosciences (Nasdaq: NBIX) will release its first quarter 2021 financial results after market close on May 5, 2021. A conference call and webcast to discuss the results will follow at 1:30 p.m. PT (4:30 p.m. ET). Participants can join via phone or by accessing the webcast on the company’s website. Neurocrine focuses on developing treatments for neurological, endocrine, and psychiatric disorders, with a portfolio that includes FDA-approved therapies for conditions such as tardive dyskinesia and Parkinson's disease.
Neurocrine Biosciences (NASDAQ: NBIX) will present key data from its movement disorders and epilepsy programs at the American Academy of Neurology's 73rd Annual Meeting, scheduled virtually from April 17-22, 2021. Highlights include findings from the KINECT 4 Phase III study on INGREZZA for tardive dyskinesia and ONGENTYS efficacy in Parkinson's disease motor fluctuations. The data also emphasize the need for simplified treatment regimens for Parkinson's patients and present genetic insights into SCN8A-related epilepsy. These findings underscore Neurocrine's commitment to addressing significant neurological challenges.
Neurocrine Biosciences (Nasdaq: NBIX) will present at the Stifel 3rd Annual CNS Day on April 1, 2021, at 12:30 p.m. ET. The presentation will feature Eiry Roberts and Kyle Gano, focusing on the company’s advancements in neuroscience treatments. Investors can access the live webcast on the company's website, with a replay available approximately one hour after the event. Neurocrine is dedicated to developing treatments for neurological, endocrine, and psychiatric disorders, and has a robust portfolio that includes FDA-approved therapies for various conditions.
Neurocrine Biosciences (Nasdaq: NBIX) presented positive Phase II data for crinecerfont, an oral CRF1 receptor antagonist, at ENDO 2021. The study showed dose-dependent reductions in androstenedione, a CAH marker, while testosterone levels remained stable, indicating potential benefits for reproductive health. The presented data also included real-world evidence on CAH's impact from the I-CAH Registry and other studies. Neurocrine aims to demonstrate crinecerfont's effectiveness in upcoming Phase III studies while addressing glucocorticoid treatment limitations in classic congenital adrenal hyperplasia patients.
Neurocrine Biosciences (Nasdaq: NBIX) will present at the Oppenheimer 31st Annual Healthcare Conference on March 16, 2021, at 4:30 p.m. ET. CFO Matt Abernethy will lead the presentation. It will be available via live webcast on the company's website, with a replay accessible one hour post-event for approximately one month. Neurocrine is a biopharmaceutical company focused on neuroscience, offering FDA-approved treatments for conditions like tardive dyskinesia and Parkinson's disease, while engaging in various clinical programs.